DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0130246A1 BENSMON Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0130246A1 BENSMON Et Al US 2013 O130246A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0130246A1 BENSMON et al. (43) Pub. Date: May 23, 2013 (54) METHODS FOR THE DETECTION, (22) Filed: Oct. 31, 2012 VISUALIZATION AND HIGH RESOLUTION PHYSICAL MAPPING OF GENOMIC Related U.S. Application Data REARRANGEMENTS IN BREAST AND OVARAN CANCER GENES AND LOC (60) Provisional application No. 61/553,906, filed on Oct. BRCA1 AND BRCA2 USING GENOMIC 31, 2011. MORSE CODE IN CONJUNCTION WITH MOLECULAR COMBING Publication Classification (71) Applicants: Aaron BENSIMON, Anthony (FR): (51) Int. Cl. Maurizio Ceppi, Issy-Les-Moulineaux CI2O I/68 (2006.01) (FR); Kevin Cheeseman, (52) U.S. Cl. Champigny-Sur-Marne (FR); Emmanuel CPC .................................... CI2O I/6886 (2013.01) Conseiller, Paris (FR); Pierre Walrafen, USPC ......................................................... 435/6.11 Montrouge (FR) (57) ABSTRACT (72) Inventors: Aaron BENSIMON, Anthony (FR): Maurizio Ceppi, Issy-Les-Moulineaux Methods for detecting genomic rearrangements in BRCA1 (FR); Kevin Cheeseman, and BRCA2 genes at high resolution using Molecular Comb Champigny-Sur-Marne (FR); Emmanuel ing and for determining a predisposition to a disease or dis Conseiller, Paris (FR); Pierre Walrafen, order associated with these rearrangements including predis Montrouge (FR) position to ovarian cancer or breast cancer. Primers useful for producing probes for this method and kits for practicing the (21) Appl. No.: 13/665,404 methods. Patent Application Publication May 23, 2013 Sheet 1 of 12 US 2013/0130246 A1 85925 379 o : 98. xxxxxx& 3850,75800 :g i s Patent Application Publication May 23, 2013 Sheet 2 of 12 US 2013/0130246 A1 Fig. 1B 845 3.25° 42950 888 O 3690 73800 O700 147600' S. : s 7250, Patent Application Publication May 23, 2013 Sheet 3 of 12 US 2013/0130246 A1 §§§§§§§ gaeae,§§§§** *& ¿(gael ***…) *& Patent Application Publication May 23, 2013 Sheet 4 of 12 US 2013/0130246 A1 s 8x8xx s a ex, N S.& xxx8. wax S. 3. er St. (x : . 8: & s ::::::::::: -: 3. S. 3: NS:8. sgy *i: g.- s: : wa s o & sxxxx Patent Application Publication May 23, 2013 Sheet 5 of 12 US 2013/0130246 A1 ******************************* Patent Application Publication May 23, 2013 Sheet 6 of 12 US 2013/0130246 A1 xxxxxxxxxx $$,žš. wo-wox. -swww.sax888 Patent Application Publication May 23, 2013 Sheet 7 of 12 US 2013/0130246 A1 apoi $$33.3.8 (9eseo)cpººxa?ed |e$$ eiwsiera?avsvozizzzzzzzszez ? Patent Application Publ ication May 23, 2013 Sheet 8 of 12 US 2013/0130246 A1 (zeseo)zxa? $?% 3888-8-8 Patent Application Publication May 23, 2013 Sheet 9 of 12 US 2013/0130246 A1 *· : *****?inxe.------- ***¿. ***?….. *«». *& Patent Application Publicat O May 23, 2013 Sheet 10 of 12 US 2013/0130246 A1 qwzºg-/+z^9?ouo?eolidna! oz-gpxednd |9|8 | 9·61 Patent Application Publication May 23, 2013 Sheet 11 of 12 US 2013/0130246 A1 vae,ºžk? Patent Application Publication May 23, 2013 Sheet 12 of 12 US 2013/0130246 A1 sax £892eup&#38 US 2013/0130246 A1 May 23, 2013 METHODS FOR THE DETECTION, amplification (MLPA) (Casilli et al., 2002), (Hofmann et al., VISUALIZATION AND HIGH RESOLUTION 2002) and high-resolution oligonucleotide array comparative PHYSICAL MAPPING OF GENOMIC genomic hybridization (aCGH) (Rouleau et al., 2007), (Staaf REARRANGEMENTS IN BREAST AND et al., 2008). New approaches that provide both prescreening OVARAN CANCER GENES AND LOC and quantitative information, such as qPCR-HRM and BRCA1 AND BRCA2 USING GENOMIC EMMA, have recently been developed and genomic capture MORSE CODE IN CONJUNCTION WITH combined with massively parallel sequencing has been pro MOLECULAR COMBING posed for simultaneous detection of Small mutations and large rearrangements affecting 21 genes involved in breast CROSS-REFERENCE TO RELATED and ovarian cancer (Walsh et al., 2010). APPLICATIONS 0008 Molecular Combing is a powerful FISH-based tech 0001. The present application claims priority to U.S. Pro nique for direct visualization of single DNA molecules that visional Application No. 61/553,906, filed Oct. 31, 2011, the are attached, uniformly and irreversibly, to specially treated entire contents of which are incorporated herein by reference. glass surfaces (Herrick and Bensimon, 2009): (Schurra and On Oct. 30, 2012, an International Application (PCT/ Bensimon, 2009). This technology considerably improves IBF ; Submission number 1000168920) was also filed the structural and functional analysis of DNA across the with the same title, the entire contents of which are incorpo genome and is capable of visualizing the entire genome at rated herein by reference. high resolution (in the kb range) in a single analysis. Molecu lar Combing is particularly Suited to the detection of genomic BACKGROUND OF THE INVENTION imbalances such as mosaicism, loss of heterozygosity (LOH), copy number variations (CNV), and complex rearrangements 0002 1. Field of the Invention such as translocations and inversions (Caburet et al., 2005), 0003. The invention relates to a method for detecting thus extending the spectrum of mutations potentially detect genomic rearrangements in BRCA1 and BRCA2 genes and able in breast cancer genes. Molecular Combing has been loci at high resolution using Molecular Combing and relates Successfully employed for the detection of large rearrange to a method of determining a predisposition to diseases or ments in BRCA1 (Gadet al., 2001), (Gadet al., 2002a), (Gad disorders associated with these rearrangements including et al., 2003) and BRCA2 (Gad et al., 2002b), using a first predisposition to ovarian cancer or breast cancer. generation “color bar coding screening approach. However, 0004 2. Description of the Related Art these techniques lack resolution and cannot precisely detect 0005 Breast cancer is the most common malignancy in large rearrangements in and around BRCA1 and BRCA2. women, affecting approximately 10% of the female popula 0009. In distinction to the prior art techniques, as disclosed tion. Incidence rates are increasing annually and it is esti herein, the inventors provide a novel Genetic Morse Code mated that about 1.4 million women will be diagnosed with Molecular Combing procedure that provides for high resolu breast cancer annually worldwide and about 460,000 will die tion visual inspection of genomic DNA samples, precise from the disease. Germline mutations in the hereditary breast mapping of mutated exons, precise measurement of mutation and ovarian cancer Susceptibility genes BRCA1 size with robust statistics, simultaneous detection of BRCA1 (MIMH1 13705) and BRCA2 (MIMH600185) are highly pen and BRCA2 genetic structures or rearrangements, detection etrant (King et al., 2003), (Nathanson et al., 2001). Screening of genetic inversions or translocations, and Substantial elimi is important for genetic counseling of individuals with a nation of problems associated with repetitive DNA sequences positive family history and for early diagnosis or prevention such as Alu sequences in BRCA1 and BRCA2 loci. in mutation carriers. When a BRCA1 or BRCA2 mutation is identified, predictive testing is offered to all family members BRIEF SUMMARY OF THE INVENTION older than 18 years. If a woman tests negative, her risk becomes again the risk of the general population. If she tests (0010. The BRCA1 and BRCA2 genes are involved, with positive, a personalized Surveillance protocol is proposed: it high penetrance, in breast and ovarian cancer Susceptibility. includes mammographic screening from an early age, and About 2% to 4% of breast cancer patients with a positive possibly prophylactic Surgery. Chemoprevention of breast family history who are negative for BRCA1 and BRCA2 cancer with anti-estrogens is also currently tested in clinical point mutations can be expected to carry large genomic alter trial and may be prescribed in the future. ations (deletion or duplication) in one of the two genes, and 0006 Most deleterious mutations consist of either small especially BRCA1. However, large rearrangements are frameshifts (insertions or deletions) or point mutations that missed by direct sequencing. Molecular Combing is a pow give rise to premature stop codons, missense mutations in erful FISH-based technique for direct visualization of single conserved domains, or splice-site mutations resulting in aber DNA molecules, allowing the entire genome to be examined rant transcript processing (Szabo et al., 2000). However, at high resolution in a single analysis. A novel predictive mutations also include more complex rearrangements, genetic test based on Molecular Combing is disclosed herein. including deletions and duplications of large genomic regions For that purpose, specific BRCA1 and BRCA2 “Genomic that escape detection by traditional PCR-based mutation Morse Codes” (GMC) were designed, covering coding and screening combined with DNA sequencing (Mazoyer, 2005). non-coding regions and including large genomic portions 0007 Techniques capable of detecting these complex flanking both genes. The GMC is a series of colored signals rearrangements include Southern blot analysis combined distributed along a specific portion of the genomic DNA with long-range PCR or the protein truncation test (PTT), which signals arise from probe hybridization with the probes quantitative multiplex PCR of short fluorescent fragments of the invention. The concept behind the GMC has been (QMPSF) (Hofmannet al., 2002), real-time PCR, fluorescent previously defined in WIPO patent application WO/2008/ DNA microarray assays, multiplex ligation-dependent probe 028931
Load more

Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • TMEM106B in Humans and Vac7 and Tag1 in Yeast Are Predicted to Be Lipid Transfer Proteins
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.12.435176; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. TMEM106B in humans and Vac7 and Tag1 in yeast are predicted to be lipid transfer proteins Tim P. Levine* UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, United Kingdom. ORCID 0000-0002-7231-0775 *Corresponding author and lead contact: [email protected] Data availability statement: The data that support this study are freely available in Harvard Dataverse at https://dataverse.harvard.edu/dataverse/LEA_2. Acknowledgements: work was funded by the Higher Education Funding Council for England and the NIHR Moorfields Biomedical Research Centre Conflict of interest disclosure: the author declares that there is no conflict of interest Keywords: Structural bioinformatics, Lipid transfer protein, LEA_2, TMEM106B, Vac7, YLR173W, Endosome, Lysosome Running Title: TMEM106B & Vac7: lipid transfer proteins 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.12.435176; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract TMEM106B is an integral membrane protein of late endosomes and lysosomes involved in neuronal function, its over-expression being associated with familial frontotemporal lobar degeneration, and under-expression linked to hypomyelination. It has also been identified in multiple screens for host proteins required for productive SARS-CoV2 infection. Because standard approaches to understand TMEM106B at the sequence level find no homology to other proteins, it has remained a protein of unknown function.
    [Show full text]
  • Anti-TMEM106A (RABBIT) Antibody - 600-401-FH1
    Anti-TMEM106A (RABBIT) Antibody - 600-401-FH1 Code: 600-401-FH1 Size: 100 µg Product Description: Anti-TMEM106A (RABBIT) Antibody - 600-401-FH1 Concentration: 1 mg/mL by UV absorbance at 280 nm PhysicalState: Liquid (sterile filtered) Label Unconjugated Host Rabbit Gene Name TMEM106A Species Reactivity Human, mouse Buffer 0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2 Stabilizer None Preservative 0.02% (w/v) Sodium Azide Storage Condition Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use. Synonyms TMEM106A Antibody, Transmembrane protein 106A Application Note Anti-TMEM106A Antibody has been tested for use in ELISA, Western Blotting, Immunohistochemistry and Immunofluorescence. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 29 kDa in Western Blots of specific cell lysates and tissues. Background Transmembrane protein 106A (TMEM106A) is a single-pass transmembrane protein that is closely related to TMEM106B, a protein that is thought to be a novel risk factor for frontotemporal lobar degeneration (FTLD), a group of clinically, pathologically and genetically heterogeneous disorders associated with atrophy in the frontal lobe and temporal lobe of the brain. The actual roles of TMEM106A and TMEM106B are still undetermined; however, as TMEM106B is involved in FTLD, it is possible that TMEM106A may also be a risk factor for FTLD.
    [Show full text]
  • Increased Expression of the Frontotemporal Dementia Risk Factor Tmem106b Causes C9orf72-Dependent Alterations in Lysosomes
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2016 Increased Expression of Frontotemporal Dementia Risk Factor Tmem106b Alters Lysosomal and Autophagosomal Pathways Johanna Irene Busch University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Cell Biology Commons, and the Neuroscience and Neurobiology Commons Recommended Citation Busch, Johanna Irene, "Increased Expression of Frontotemporal Dementia Risk Factor Tmem106b Alters Lysosomal and Autophagosomal Pathways" (2016). Publicly Accessible Penn Dissertations. 1630. https://repository.upenn.edu/edissertations/1630 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1630 For more information, please contact [email protected]. Increased Expression of Frontotemporal Dementia Risk Factor Tmem106b Alters Lysosomal and Autophagosomal Pathways Abstract Frontotemporal lobar degeneration (FTLD) is an important cause of dementia in individuals under age 65. Common variants in the TMEM106B gene were previously discovered by genome-wide association (GWAS) to confer genetic risk for FTLD-TDP, the largest neuropathological subset of FTLD (p=1x10-11, OR=1.6). Prior to its discovery in the GWAS, TMEM106B, or Transmembrane Protein 106B, was uncharacterized. To further understand the role of TMEM106B in disease pathogenesis, we used immortalized as well as primary neurons to assess the cell biological effects of disease-relevant levels of TMEM106B overexpression and the interaction of TMEM106B with additional disease-associated proteins. We also employed immunostaining to assess its expression pattern in human brain from controls and FTLD cases. We discovered that TMEM106B is a highly glycosylated, Type II late endosomal/lysosomal transmembrane protein. We found that it is expressed by neurons, glia, and peri-vascular cells in disease- affected and unaffected regions of human brain from normal controls in a cytoplasmic, perikaryal distribution.
    [Show full text]
  • SUPPLEMENTARY MATERIAL Supplementary Fig. S1. LD Mice Used in This Study Accumulate Polyglucosan Inclusions (Lafora Bodies) in the Brain
    1 SUPPLEMENTARY MATERIAL Supplementary Fig. S1. LD mice used in this study accumulate polyglucosan inclusions (Lafora bodies) in the brain. Samples from the hippocampus of five months old control, Epm2a-/- (lacking laforin) and Epm2b-/- mice (lacking malin) were stained with periodic acid Schiff reagent (PAS staining), which colors polysaccharide granules in red. Bar: 50 m. Supplementary Fig. S2. Principal component analysis (PCA) representing the first two components with the biggest level of phenotypic variability. Samples 1_S1 to 4_S4 corresponded to control, 5_S5, 6_S6 and 8_S8 to Epm2a-/- and 9_S9 to 12_S12 to Epm2b- /- samples, of animals of 16 months of age respectively. Supplementary Table S1. Primers used in this work to validate the expression of the corresponding genes by RT-qPCR. Supplementary Table S2: Genes downregulated more than 0.5 fold in Epm2a-/- and Epm2b-/- mice of 16 months of age. The gene name, false discovery rate (FDR), fold change (FC), description and MGI Id (mouse genome informatics) are indicated. Genes are arranged according to FC. Supplementary Table S3: Genes upregulated more than 1.5 fold in Epm2a-/- mice of 16 months of age. The gene name, false discovery rate (FDR), fold change (FC), description and MGI Id (mouse genome informatics) are indicated. Genes are arranged according to FC. Supplementary Table S4: Genes upregulated more than 1.5 fold in Epm2b-/- mice of 16 months of age. The gene name, false discovery rate (FDR), fold change (FC), description and MGI Id (mouse genome informatics) are indicated. Genes are arranged according to FC. 2 Supplementary Table S5: Genes upregulated in both Epm2a-/- and Epm2b-/- mice of 16 months of age.
    [Show full text]
  • Transmembrane Protein 106A Activates Mouse Peritoneal Macrophages Via the MAPK and NF-Κb Signaling Pathways
    www.nature.com/scientificreports OPEN Transmembrane protein 106a activates mouse peritoneal macrophages via the MAPK and Received: 06 January 2015 Accepted: 30 June 2015 NF-κB signaling pathways Published: 28 July 2015 Hui Dai1, Dong Xu1,2, Jing Su3, Jingyuan Jang1 & Yingyu Chen1,2 The M1 and M2 states of macrophage are the two extremes of a physiologic/phenotypic continuum that is dynamically influenced by environmental signals. Molecular mechanism analysis indicated that they gain M1 and M2-related functions after encountering specific ligands in the tissue environment. Here, we first characterized the previously unknown immunobiological functions of mouse Tmem106a. This protein is abundantly expressed on the surface of mouse macrophages. Activation of Tmem106a by stimulation with anti-Tmem106a upregulated the expression of CD80, CD86, CD69 and MHC II on macrophage, and induced the release of TNF-α, IL-1β, IL-6, CCL2 and NO, but not IL-10. These effects were largely abrogated by pretreatment with siRNA against Tmem106a. Notably, anti-Tmem106a significantly increased iNOS production and phosphorylation of STAT1, and had no effect on the ARGINASE-1 or p-STAT6 level, indicating that anti-Tmem106a activated macrophages and polarized them into M1-like macrophages. Further analysis found that anti-Tmem106a stimulation increased phosphorylation of ERK-1/2, JNK, p38 MAPK, NF-κB p65 and IKKα/β, and promoted nuclear translocation of the cytosolic NF-κB p65 subunit. Collectively, these data suggest that mouse Tmem106a might be a new trigger of macrophage activation and have some influence toward the M1 state through the activation of the MAPKs and NF-κB pathway.
    [Show full text]
  • Identification and Comprehensive Characterization of Large Genomic
    Identification and comprehensive characterization of large genomic rearrangements in the and genes Jesús Valle, Lídia Feliubadaló, Marga Nadal, Alex Teulé, Rosa Miró, Raquel Cuesta, Eva Tornero, Mireia Menéndez, Esther Darder, Joan Brunet, et al. To cite this version: Jesús Valle, Lídia Feliubadaló, Marga Nadal, Alex Teulé, Rosa Miró, et al.. Identification and com- prehensive characterization of large genomic rearrangements in the and genes. Breast Cancer Re- search and Treatment, Springer Verlag, 2009, 122 (3), pp.733-743. 10.1007/s10549-009-0613-9. hal- 00535410 HAL Id: hal-00535410 https://hal.archives-ouvertes.fr/hal-00535410 Submitted on 11 Nov 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Breast Cancer Res Treat (2010) 122:733–743 DOI 10.1007/s10549-009-0613-9 PRECLINICAL STUDY Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes Jesu´s del Valle • Lı´dia Feliubadalo´ • Marga Nadal • Alex Teule´ • Rosa Miro´ • Raquel Cuesta • Eva Tornero • Mireia Mene´ndez • Esther Darder • Joan Brunet • Gabriel Capella` • Ignacio Blanco • Conxi La´zaro Received: 26 August 2009 / Accepted: 20 October 2009 / Published online: 6 November 2009 Ó Springer Science+Business Media, LLC.
    [Show full text]
  • Downloaded a Meta
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.18.210328; this version posted April 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dynamic regulatory module networks for inference of cell type-specific transcriptional networks Alireza Fotuhi Siahpirani1,2,+, Sara Knaack1+, Deborah Chasman1,8,+, Morten Seirup3,4, Rupa Sridharan1,5, Ron Stewart3, James Thomson3,5,6, and Sushmita Roy1,2,7* 1Wisconsin Institute for Discovery, University of Wisconsin-Madison 2Department of Computer Sciences, University of Wisconsin-Madison 3Morgridge Institute for Research 4Molecular and Environmental Toxicology Program, University of Wisconsin-Madison 5Department of Cell and Regenerative Biology, University of Wisconsin-Madison 6Department of Molecular, Cellular, & Developmental Biology, University of California Santa Barbara 7Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison 8Present address: Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Wisconsin-Madison +These authors contributed equally. *To whom correspondence should be addressed. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.18.210328; this version posted April 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Multi-omic datasets with parallel transcriptomic and epigenomic measurements across time or cell types are becoming increasingly common.
    [Show full text]
  • The Pdx1 Bound Swi/Snf Chromatin Remodeling Complex Regulates Pancreatic Progenitor Cell Proliferation and Mature Islet Β Cell
    Page 1 of 125 Diabetes The Pdx1 bound Swi/Snf chromatin remodeling complex regulates pancreatic progenitor cell proliferation and mature islet β cell function Jason M. Spaeth1,2, Jin-Hua Liu1, Daniel Peters3, Min Guo1, Anna B. Osipovich1, Fardin Mohammadi3, Nilotpal Roy4, Anil Bhushan4, Mark A. Magnuson1, Matthias Hebrok4, Christopher V. E. Wright3, Roland Stein1,5 1 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 2 Present address: Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 3 Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 4 Diabetes Center, Department of Medicine, UCSF, San Francisco, California 5 Corresponding author: [email protected]; (615)322-7026 1 Diabetes Publish Ahead of Print, published online June 14, 2019 Diabetes Page 2 of 125 Abstract Transcription factors positively and/or negatively impact gene expression by recruiting coregulatory factors, which interact through protein-protein binding. Here we demonstrate that mouse pancreas size and islet β cell function are controlled by the ATP-dependent Swi/Snf chromatin remodeling coregulatory complex that physically associates with Pdx1, a diabetes- linked transcription factor essential to pancreatic morphogenesis and adult islet-cell function and maintenance. Early embryonic deletion of just the Swi/Snf Brg1 ATPase subunit reduced multipotent pancreatic progenitor cell proliferation and resulted in pancreas hypoplasia. In contrast, removal of both Swi/Snf ATPase subunits, Brg1 and Brm, was necessary to compromise adult islet β cell activity, which included whole animal glucose intolerance, hyperglycemia and impaired insulin secretion. Notably, lineage-tracing analysis revealed Swi/Snf-deficient β cells lost the ability to produce the mRNAs for insulin and other key metabolic genes without effecting the expression of many essential islet-enriched transcription factors.
    [Show full text]
  • Datasheet Blank Template
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . TMEM106A (S-18): sc-248863 BACKGROUND SOURCE TMEM106A (transmembrane protein 106A) is a 262 amino acid protein encod - TMEM106A (S-18) is an affinity purified goat polyclonal antibody raised ed by a gene mapping to human chromosome 17. Chromosome 17 makes up against a peptide mapping within an internal region of TMEM106A of over 2.5% of the human genome with about 81 million bases encoding over mouse origin. 1,200 genes. Two key tumor suppressor genes are associated with chromo - some 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for PRODUCT maintenance of cellular genetic integrity by moderating cell fate through DNA Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide repair versus cell death. Malfunction or loss of p53 expression is associated and 0.1% gelatin. with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genet - Blocking peptide available for competition studies, sc-248863 P, (100 µg ic determinant of early onset breast cancer and predisposition to cancers of peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA). the ovary, colon, prostate gland and fallopian tubes. Chromosome 17 is also linked to neurofibromatosis, a condition characterized by neural and epider - APPLICATIONS mal lesions, and dysregulated Schwann cell growth. Alexander disease, Birt- TMEM106A (S-18) is recommended for detection of TMEM106A of mouse Hogg-Dube syndrome and Canavan disease are also associated with chro - and rat origin by Western Blotting (starting dilution 1:200, dilution range mosome 17.
    [Show full text]
  • Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared Amongst Δγ T, Innate Lymphoid, and Th Cells
    Downloaded from http://www.jimmunol.org/ by guest on September 26, 2021 δγ is online at: average * The Journal of Immunology , 10 of which you can access for free at: 2016; 197:1460-1470; Prepublished online 6 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600643 http://www.jimmunol.org/content/197/4/1460 Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared amongst T, Innate Lymphoid, and Th Cells You Jeong Lee, Gabriel J. Starrett, Seungeun Thera Lee, Rendong Yang, Christine M. Henzler, Stephen C. Jameson and Kristin A. Hogquist J Immunol cites 41 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2016/07/06/jimmunol.160064 3.DCSupplemental This article http://www.jimmunol.org/content/197/4/1460.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 26, 2021. The Journal of Immunology Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared amongst gd T, Innate Lymphoid, and Th Cells You Jeong Lee,* Gabriel J.
    [Show full text]
  • The Roles of Progranulin and Tmem106b in Lysosomal
    THE ROLES OF PROGRANULIN AND TMEM106B IN LYSOSOMAL PHYSIOLOGY AND NEURODEGENERATIVE DISEASE A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Daniel Harris Paushter May 2018 © 2018 Daniel Harris Paushter THE ROLES OF PROGRANULIN AND TMEM106B IN LYSOSOMAL PHYSIOLOGY AND NEURODEGENERATIVE DISEASE Daniel Harris Paushter, Ph.D. Cornell University 2018 Frontotemporal lobar degeneration (FTLD) is a devastating, clinically heterogeneous neurodegenerative disease that results in the progressive atrophy of the frontal and temporal lobes of the brain. Most often presenting with drastic alterations in personality and behavior, as well as a gradual decline in language capabilities, FTLD is the second leading cause of early-onset dementia only after Alzheimer’s disease. One of the major causes of familial FTLD is haploinsufficiency of the protein, progranulin (PGRN), resulting from mutation in the granulin (GRN) gene. Interestingly, PGRN shows a dosage-dependent disease correlation, and GRN mutation resulting in complete loss of PGRN causes the lysosomal storage disease (LSD), neuronal ceroid lipofuscinosis (NCL). In this text, my co-workers and I demonstrate that PGRN is proteolytically processed in the lysosome into discrete granulin peptides, which may possess distinct functions. We have independently found interactions between PGRN or granulin peptides and three lysosomal hydrolases: Cathepsin D (CTSD), glucocerebrosidase (GBA), and ɑ-N-acetylgalactosaminidase (NAGA). The activity of each of these enzymes was found to be reduced in Grn-/- mice, indicating that a potential mechanism of PGRN-related disease may be dysfunction of multiple lysosomal hydrolases. In addition to possessing an indeterminate lysosomal function, PGRN has also been shown to be a neurotrophic factor.
    [Show full text]